Gsk Share Discussion Threads

[wallywoo] 07/12/2022 08:03

Hmm 8am auction. Looking good!!

[our haven] 07/12/2022 07:51

Unfortunately you have to expect speculative litigation and set aside funds to defend against as a cost of doing business in the US. Good news that this one is dismissed though.

[tuftymatt] 07/12/2022 07:45

A positive statement so lets hope the price recovers and we push towards 1475 min before Christmas now.

[bountyhunter] 07/12/2022 07:16

Issued: 07 December 2022, London UK

Statement: Zantac (ranitidine) litigation


-- MDL Court has dismissed all cases alleging the five remaining cancers in the MDL
-- Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

[grahamburn] 06/12/2022 21:11

Thanks. Maybe an RNS tomorrow......

[grahamburn] 06/12/2022 20:47

Can't read whole article as don't want to register, but the intro to it doesn't say GSK and HLN won the case - it says GSK and Sanofi won. However, it does say that GSK and HLN went up as a consequence of the outcome.

[bountyhunter] 06/12/2022 20:24

Short up by nearly 10% this evening in New York!

[netcurtains] 06/12/2022 20:06

The article says both GSK and HLN won a litigation case.

Is this specific case a really important thing?

[spoole5] 06/12/2022 19:36

Currently up 10% in the US

[spoole5] 06/12/2022 19:23

https://seekingalpha.com/news/3914497-glaxosmithkline-sanofi-gain-after-win-in-zantac-case

[geckotheglorious] 06/12/2022 19:23

GlaxoSmithKline, Sanofi gain after win in Zantac case

GlaxoSmithKline (NYSE:GSK) rose 4.4% and Sanofi (NASDAQ:SNY) gained 4% after winning in a Zantac product liability lawsuit. Haleon (NYSE:HLN) advanced 3.8%.
The companies were granted summary judgement by federal court in multi district litigation.

"As a result, if the plaintiff does not have this evidence, there is no genuine dispute of material fact, and the defendant is entitled to judgement as a matter of law," according to the judge's decision.
Developing story ...

[abdullla] 06/12/2022 16:57

Not allowed to rise above £14 .

[mj19] 06/12/2022 16:52

Why such a drop

[geckotheglorious] 05/12/2022 17:50

Blister1

You're welcome.
I may not be currently invested but I keep a cursory glance at news for GSK/AZN and Pfizer.

And the BB's are meant to be about ensuring most see "pertinent news"

:)

[alibizzle] 05/12/2022 16:28

In the unlikely event of Novartis bid it will be rejected as was Unilever . I hope not , but I'm sure it will

[geckotheglorious] 05/12/2022 16:10

Bilster1
last week.

GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.

The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.

In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.

Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.

[tuftymatt] 05/12/2022 15:28

Nice little uptick 👍🏻

[bilster1] 05/12/2022 15:20

Where have you heard that from? How nice would that be!

[pol123] 05/12/2022 15:05

I give GSK 24 months max. GSK will be taken out IMO if price remains. Any positive news on the Daubert hearings and we will rally, not sure what level £15+ I expect

[palfrey man] 05/12/2022 15:05

Hold on, rumours of a possible bid for gsk from Novartis spreading.

[geckotheglorious] 05/12/2022 14:55

The ADRs of GSK plc (NYSE:GSK) dropped ~1% pre-market Monday after Bank of America downgraded its shares to Underperform from Neutral, arguing that the British drugmaker remains the firm’s least preferred name among the European majors.

Despite an “undemanding” PE multiple for 2024, “we see insufficient catalysts to rerate (GSK) shares near-term,” the analysts led by Graham Parry wrote, slashing their price target on the stock to 1450p from 1640p.

Noting the ~ £4B free cash flow the company generates, the analysts expect claims related to heartburn medication Zantac to weigh on GSK shares which, according to the analysts, more than discount their base case $4B liability risk.

Despite encouraging Phase 3 data, the analysts see no reason for GSK’s RSV vaccine to outcompete a rival shot from Pfizer (PFE). They also point out that the company has indicated a slower ramp for the RSV vaccine compared to its shingles vaccine Shingrix given the need to educate the public/physicians on the disease.

“While encouraged by GSK’s strong RSV vaccine PIII data we view Pfizer’s vaccine as credible competition given little to no perceived differentiation on efficacy and worse reactogenicity (tolerability) for GSK,” the team wrote.

They also argue that the company’s key franchises remain under pressure and a weak pipeline is unlikely to avoid an upcoming patent cliff in 2028/29E for HIV medication dolutegravir made worse by recent setbacks, including the recall of blood cancer therapy Blenrep.

[anhar] 05/12/2022 09:34

As purely an income investor that trades only rarely, I'm hanging on to my existing holding of GSK and my HLN allocation, but I see no reason to increase either for the time being, and haven't for years now for the pre-demerger GSK, because of the dull income prospects. Both shares fit into my port on diversification grounds, a factor which is crucial to my strategy, but offer little current income attractions against other more desirable shares in the port or potential new stocks.